Sep 14, 2016
There are new concerns arising in Japan around drug pricing. Last April, the Japanese government introduced a re-pricing rule for “huge seller drugs” and proceeded to slash the reimbursement price for Gilead’s Solvaldi by a hefty 30%. The concern now among industry...
Jul 25, 2016
Many Japanese pharmaceutical companies are now “global” in terms of scope and size. Companies like Takeda, Astellas, and Daiichi Sankyo have established their commercial footprint around the world. Accordingly, the business development teams at these companies are...
Jun 21, 2016
Locust Walk is pleased to announce that our client, Medgenics, Inc. (NYSE: MDGN), has entered into a collaboration with Kyowa Hakko Kirin Co., Ltd. for the development and commercialization of Kyowa Hakko Kirin’s first-in-class anti-LIGHT monoclonal antibody. Locust...
